Lawrence A. Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
Associate Director, Clinical Nutrition and Risk Factor Modification Centre
St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario
Canada

Video

What is the rationale for a new category called “extreme risk,” introduced by AACE in which they designate a threshold LDL-C target of 55 mg/dL?

Lawrence Leiter, MD, FRCP(C), FACP

Video

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

Lawrence Leiter, MD, FRCP(C), FACP

Video

What is the profile of the diabetic patient in whom the diabetes specialist should strongly consider the LDL-C lowering and outcome-improving effects of PCSK9 inhibitors? How do we risk stratify populations for secondary prevention?

Lawrence Leiter, MD, FRCP(C), FACP

Video

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group?

Lawrence Leiter, MD, FRCP(C), FACP